Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs

American Journal of Veterinary Research

Volumn 74, Issue 2, 2013, Pages 275-280

  Fischer, Kristin M ^a   Ward, Daniel A ^a   Hendrix, Diane V H ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; FLUORESCEIN; OLIVE OIL;

ANIMAL EXPERIMENT; AQUEOUS HUMOR FLOW; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; FEMALE; FLUOROPHOTOMETRY; INTRAOCULAR PRESSURE; MALE; NONHUMAN; OCULOPLETHYSMOGRAPHY; SLIT LAMP;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CONTRAST MEDIA; CROSS-OVER STUDIES; DOGS; FEMALE; FLUORESCEIN; FLUOROPHOTOMETRY; INTRAOCULAR PRESSURE; LONGITUDINAL STUDIES; MALE; TETRAHYDROCANNABINOL; TONOMETRY, OCULAR;

EID: 84873384667     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.2.275     Document Type: Article

References (52)

1. Martin CL. Glaucoma, in Proceedings. 44th Annu Meet Am Anim Hosp Assoc 1977;301-303.
2. Gelatt KN, MacKay EO. Prevalence of the breed-related glaucomas in pure-bred dogs in North America. Vet Ophthalmol 2004;7:97-111.
3. Gelatt KN. Visual disturbance: where do I look? J Small Anim Pract 1997;38:328-335.
4. Qu J, Wang D, Grosskreutz CL. Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res 2010;91:48-53.
5. Gelatt KN, Brooks DE, Mallberg ME. The canine glaucomas. In: Gelatt KN, ed. Veterinary ophthalmology. 4th ed. Ames, Iowa: Blackwell, 2007;753-811.
6. Caprioli J, Varma R. Intraocular pressure: modulation as treatment for glaucoma. Am J Ophthalmol 2011;152:340-344.
7. Abrams KL. Medical and surgical management of the glaucoma patient. Clin Tech Small Anim Pract 2001;16:71-76.
8. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol 2004;88:708-713.
9. Russo E. History of cannabis as a medicine. In: Guy GW, Whittle BA, Robson PJ, eds. The medicinal uses of cannabis and cannabinoids. 4th ed. Chicago: Pharmaceutical Press, 2004;1-16.
10. Frankhauser M. History of cannabis in western medicine: pharmacology, toxicology and therapeutic potential. In: Grotenhermen F, Russo E, eds. Cannabis and cannabinoids. Binghampton, NY: The Haworth Integrative Healing Press, 2002;37-51.
11. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006;28:153-157.
12. Gerra G, Zaimovic A, Gerra ML, et al. Pharmacology and toxicology of cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov 2010;5:46-52.
13. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 2010;160:480-498.
14. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009;6:713-737.
15. Hepler RS, Frank IR. Marihuana smoking and intraocular pressure (lett). JAMA 1971;217:1392.
16. Dixon W. The pharmacology of Cannabis indica. Br Med J (Clin Res Ed) 1899;2:1354-1357.
17. Zhan GL, Camras CB, Palmberg PF, et al. Effects of marijuana on aqueous humor dynamics in a glaucoma patient. J Glaucoma 2005;14:175-177.
18. Innemee HC, Hermans AJM, Zwieten PA. The influence of delta- 9-tetrahydrocannabinol on intraocular pressure in the anaesthetized cat. Doc Ophthalmol 1980;48:235-241.
19. Green K, Symonds CM, Oliver NW, et al. Intraocular pressure following systemic administration of cannabinoids. Curr Eye Res 1982-1983;2:247-253.
20. Elsohly MA, Harland EC, Benigni DA, et al. Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit. Curr Eye Res 1984;3:841-850.
21. Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc 2002;100:215-224.
22. Green K, Bigger JF, Kim K, et al. Cannabinoid penetration and chronic effects in the eye. Exp Eye Res 1977;24:197-205.
23. Green K, Wynn H, Bowman KA. A comparison of topical cannabinoids on intraocular pressure. Exp Eye Res 1978;27:239-246.
24. Merritt JC, Olsen JL, Armstrong JR, et al. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol 1981;33:40-41.
25. Merritt JC, Perry DD, Russell DN, et al. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol 1981;21(suppl 8-9):467S-471S.
26. Chiang CW, Barnett G, Brine D. Systemic absorption of delta 9-tetrahydrocannabinol after ophthalmic administration to the rabbit. J Pharm Sci 1983;72:136-138.
27. Jay WM, Green K. Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes. Arch Ophthalmol 1983;101:591-593.
28. Muchtar S, Almog S, Torracca MT, et al. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. Ophthalmic Res 1992;24:142-149.
29. Green KE, Kearse CE. Ocular penetration of topical delta-9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr Eye Res 2000;21:566-570.
30. Kearse EC, Green K. Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of delta-9-tetrahydrocannabinol. Curr Eye Res 2000;20:496-501.
31. Chien FY, Wang R-F, Mittag TW, et al. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch Ophthalmol 2003;121:87-90.
32. Thompson GR, Yang CL. Comparative toxicities of tetrahydropyridobenzopyrans. In: Cohen S, Stillman RC, eds. The therapeutic potential of marihuana. New York: Plenum Publishing, 1976;457-473.
33. Ward DA, Cawrse MA, Hendrix DV. Fluorophotometric determination of aqueous humor flow rate in clinically normal dogs. Am J Vet Res 2001;62:853-858.
34. Jones RF, Maurice DM. New methods of measuring the rate of aqueous flow in man with fluorescein. Exp Eye Res 1966;5:208-220.
35. Yablonski ME, Zimmerman TJ, Waltman SR, et al. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res 1978;27:135-142.
36. Smith LN, Miller PE, Felchle LM. Effects of topical administration of latanoprost, timolol, or a combination of latanoprost and timolol on intraocular pressure, pupil size, and heart rate in clinically normal dogs. Am J Vet Res 2010;71:1055-1061.
37. Gelatt KN, MacKay EO. Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous Beagle. J Ocul Pharmacol Ther 2002;18:525-534.
38. Cawrse MA, Ward DA, Hendrix DV. Effects of topical application of a 2% solution of dorzolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Am J Vet Res 2001;62:859-863.
39. Plummer CE, MacKay EO, Gelatt KN. Comparison of the effects of topical administration of a fixed combination of dorzolamide- timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs. Vet Ophthalmol 2006;9:245-249.
40. Wilkie DA, Latimer CA. Effects of topical administration of timolol maleate on intraocular pressure and pupil size in dogs. Am J Vet Res 1991;52:432-435.
41. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78:539-548.
42. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
43. Straiker AJ, Maguire G, Mackie K, et al. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci 1999;40:2442-2448.
44. Corey S. Recent developments in the therapeutic potential of cannabinoids. P R Health Sci J 2005;24:19-26.
45. Järvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002;95:203-220.
46. Hepler R, Frank IM, Petrus R. Ocular effects of marihuana smoking. In: Braude MC, Szara S, eds. The pharmacology of marihuana. New York: Raven Press, 1976;815-824.
47. Green K, Kim K. Acute dose response of intraocular pressure to topical and oral cannabinoids. Proc Soc Exp Biol Med 1977;154:228-231.
48. Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol 1998;116:1433-1437.
49. Colasanti BK. Ocular hypotensive effect of marihuana cannabinoids: correlate of central action or separate phenomenon? J Ocul Pharmacol 1986;2:295-304.
50. Green K, Podos SM. Antagonism of arachidonic acid-induced ocular effects by delta1-tetrahydrocannabinol. Invest Ophthalmol 1974;13:422-429.
51. Green K, Pederson JE. Effect of 1-tetrahydrocannabinol on aqueous dynamics and ciliary body permeability in the rabbit. Exp Eye Res 1973;15:499-507.
52. Glantz SA. Primer of biostatistics. 3rd ed. New York: McGraw- Hill, 1992.